References
- Adjei AA, Schwartz B, Garmey E. (2011). Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 16:788–99
- Demetri GD, von Mehren M, Blanke CD, et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–80
- Eathiraj S, Palma R, Volckova E, et al. (2011). Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 286:20666–76
- Munshi N, Jeay S, Li Y, et al. (2010). ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544–53
- Peters S, Adjei AA. (2012). MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 9:314–26
- Rosen LS, Senzer N, Mekhail T, et al. (2011). A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754–64
- Santoro A, Rimassa L, Borbath I, et al. (2013). Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 14:55–63
- Sequist LV, von Pawel J, Garmey EG, et al. (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29:3307–15
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–32
- Wagner AJ, Goldberg JM, Dubois SG, et al. (2012). Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118:5894–902
- Yamamoto N, Murakami H, Hayashi H, et al. (2013). CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer 109:2803–9
- Yap TA, Olmos D, Brunetto AT, et al. (2011). Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271–9
- Yokozaki H. (2000). Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 50:767–77
- Zenser TV, Lakshmi VM, Davis BB. (1999). Human and Escherichia coli beta-glucuronidase hydrolysis of glucuronide conjugates of benzidine and 4-aminobiphenyl, and their hydroxy metabolites. Drug Metab Dispos 27:1064–7